NAD+ Injections vs NMN and NR Supplements: What the Human Evidence Actually Supports

Human trials show that oral NMN can raise NAD+ levels in blood. What they mostly don't show is a meaningful benefit for metabolism, body composition or performance in healthy people. A 2025 meta-analysis of randomized NMN trials found no significant improvement in fasting glucose, insulin, HbA1c, insulin resistance, BMI or blood pressure. NR trials have been similarly underwhelming on metabolic markers. For NAD+ injections and IV drips, we couldn't find randomized trials showing health or performance outcomes in healthy adults. Higher blood numbers aren't the same as results.

Why everyone wants more NAD+

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme your cells use for energy metabolism and for enzymes involved in DNA repair and cellular stress responses. Animal studies linking falling NAD+ to aging made it a longevity headline. For background on the molecule itself, see our NAD+ profile.

There are three ways the market tries to raise it:

• Precursors by mouth: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), which the body converts to NAD+.
• NAD+ injections: usually subcutaneous or intramuscular, increasingly offered through telehealth on prescription.
• IV NAD+ drips: clinic infusions, often run over hours.

Claim vs evidence

NMN: what the trials found

The most useful single source is a 2025 systematic review and meta-analysis by Chen and colleagues in Current Diabetes Reports, which pooled randomized trials of NMN in adults.

• Blood NAD+: five of the eight included trials reported increases. The authors note that blood levels may not reflect what happens inside specific tissues.
• Metabolic markers: no significant benefit for fasting glucose, fasting insulin, HbA1c or HOMA-IR. A borderline HOMA-IR signal disappeared once one trial was excluded, because its apparent effect came from the placebo group getting worse.
• Body composition and blood pressure: no significant difference in BMI or blood pressure across six trials using 250 to 1,250 mg per day.

Two trials get cited constantly:

• Yoshino 2021 (Science): 25 women with prediabetes took 250 mg per day for 10 weeks, and the study reported increased muscle insulin sensitivity and signaling. It's a real finding, but it's one small study in women with prediabetes, not trained men.
• Igarashi 2022: 42 older men took 250 mg per day for 12 weeks. Blood NAD+ rose, but glucose and lipid results weren't significant in the pooled analysis.

The review's own conclusion: its findings "do not support the use of NMN supplementation among general population" to improve metabolism, and the trials were small and short.

NR: similar story

Nicotinamide riboside has its own set of human trials. The same review summarized them as showing no benefit for glucose control, lipid profile, hepatic insulin sensitivity or glucose uptake, and no benefit for fat deposition in skeletal muscle. Whatever NR does for NAD+ metabolism, it isn't well supported as a metabolic or performance upgrade.

NAD+ injections and IV drips

This is where the marketing runs furthest ahead of the data. The pitch is that skipping digestion delivers NAD+ more directly. That might be true for blood levels in the hours after a dose. What we couldn't find, after looking, is randomized trials showing that injected or infused NAD+ improves energy, recovery, body composition, cognition or aging markers in healthy adults. If you've seen one, send it to us and we'll update this page.

Some practical points:

• NAD+ injections offered through telehealth are prescription products, and a clinician decides whether they're appropriate. They aren't FDA-approved treatments for aging or performance.
• IV drips add the cost and risks of an IV line and are usually cash-pay.
• Research-grade NAD+ sold by peptide vendors isn't sold for human use and has no approved human dose.

How to read the next NAD+ headline

New NAD+ studies come out constantly, and most headlines skip the details that matter. Four quick checks:

• Humans or animals? Much of the exciting work is in mice. Mouse lifespan results don't tell you what a supplement does for a 40-year-old lifter.
• Blood level or outcome? A rise in blood NAD+ is a surrogate marker. Ask whether anything you'd actually notice, like strength, endurance, body fat or blood sugar, changed.
• Who was studied? Results in older adults or people with prediabetes may not apply to healthy, trained men, and the reverse is also true.
• How long and how big? Most NMN trials ran for weeks with a few dozen people. That's enough to detect large effects, not subtle ones.

Regulatory status of the precursors

NMN's status as a supplement was in limbo for several years. In late September 2025, FDA said NMN is lawful in dietary supplements, after pressure and litigation from the Natural Products Association. That settles whether it can be sold. It says nothing about whether it works. Dietary supplements aren't reviewed by FDA for effectiveness before sale, and label claims vary.

So what's worth doing?

1. Train. Exercise is the most reliable lever on mitochondrial function we have. Our MOTS-c post makes the point that hard training already raises the signals people try to buy.
2. If you want to try a precursor, treat it as an experiment with modest expectations. Pick a product with third-party testing, and don't expect measurable performance changes.
3. If you're considering injections or IV, ask the clinician what outcome they expect, how you'll measure it, and what evidence they're relying on.
4. Compare the longevity options honestly. Our Epitalon vs NAD+ comparison and longevity hub lay out where each stands.

For a deeper, precursor-by-precursor comparison, our sister site NADvsNMN.com covers the supplement side in detail.

Options we link to

If you want to go the prescription route, these telehealth services put the decision with a licensed clinician. If you'd rather start with a precursor, NR and NMN are both sold as supplements on Amazon; choose one with third-party testing.

Dosing for prescription NAD+ is set by the prescribing clinician. Research-use-only compounds are not sold for human use and have no approved human dose. See our medical disclaimer.

Sources

• Chen F et al., Effects of nicotinamide mononucleotide on glucose and lipid metabolism in adults: a systematic review and meta-analysis of randomised controlled trials, Curr Diab Rep 2025;25:4, doi:10.1007/s11892-024-01557-z (full text), including its summaries of Yoshino 2021 and Igarashi 2022.
• Natural Products Association, Amid pressure from NPA, FDA declares NMN lawful in dietary supplements, and NutraIngredients, FDA declares NMN lawful in dietary supplements (September 30, 2025).

Frequently Asked

Keep Reading